Recently Viewed
Clear AllQuality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹9,644 Cr
Revenue (TTM)
₹1,286 Cr
Net Profit (TTM)
₹78 Cr
ROE
1.8 %
ROCE
5.5 %
P/E Ratio
123.2
P/B Ratio
4.1
Industry P/E
38.59
EV/EBITDA
30
Div. Yield
0.1 %
Debt to Equity
0.1
Book Value
₹242.6
EPS
₹11.2
Face value
1
Shares outstanding
97,790,908
CFO
₹1,018.39 Cr
EBITDA
₹1,661.00 Cr
Net Profit
₹856.57 Cr
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
---|---|---|---|---|---|---|---|
Shilpa Medicare
| 20.9 | 51.5 | 52.8 | 83.3 | 31.5 | 12.9 | 8.7 |
BSE Healthcare
| -2.6 | 5.8 | 11.7 | 19.7 | 25.9 | 22.2 | 11.0 |
BSE Small Cap
| -2.6 | 9.6 | 21.0 | 6.2 | 27.3 | 35.1 | 17.6 |
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
---|---|---|---|---|---|---|---|
Shilpa Medicare
| 154.6 | 18.7 | -48.0 | 19.9 | 59.3 | -28.1 | -37.3 |
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
---|---|---|---|---|---|---|---|---|
Shilpa Medicare
|
985.8 | 9,643.7 | 1,286.4 | 79.6 | 15.9 | 4.7 | 123.2 | 4.1 |
695.5 | 2,016.8 | 451.8 | 50.8 | 11.4 | 16.3 | 39.7 | 6.2 | |
475.9 | 7,752.2 | 2,108.1 | 266.8 | 12.5 | 11.7 | 29.1 | 3.4 | |
370.7 | 3,729.3 | 819.8 | 69.7 | 13.9 | 11.9 | 53.5 | 6.2 | |
451.0 | 2,767.3 | 559.1 | -8.7 | -10.9 | -159 | -- | 3.3 | |
5,831.0 | 9,692.5 | 1,218.1 | 251.2 | 28.1 | -- | 38.6 | 18.1 | |
882.5 | 8,141.7 | 4,632.7 | 358.2 | 14.8 | 15 | 2.3 | 3.2 | |
689.6 | 5,552.1 | 696.5 | 188.0 | 34.5 | 19.8 | 29.5 | 5.6 | |
21.5 | 2,021.0 | 466.0 | 49.4 | 10.7 | 15.1 | 40.9 | 5.9 | |
932.6 | 1,950.1 | 759.9 | 61.0 | 8.7 | 12.5 | 32 | 3.9 |
Five companies that suffered a quality dip
4 min read•By Vishal Goyal
Companies falling short of cash
2 min read•By Rajan Gulati
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (APIs), finished dosage formulations, biologicals, and other allopathic pharmaceutical preparations in India, the... United States, Europe, and internationally. It's primary oncology APIs include capecitabine, gemcitabine hydrochloride, pemetrexed, axitinib, erlotinib hydrochloride, and irinotecan hydrochloride; and non-oncology APIs, such as ambroxol, tranexmic acid, and ursodeoxycholic acid; as well as novel-drug delivery systems. The company provides contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, and lyophilized injectables. In addition, it is involved in manufacture of specialized oncology formulations; and wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India. Read more
Incorporated
1987
Chairman
Omprakash Inani
Managing Director
Vishnukant Bhutada
Headquarters
Raichur, Karnataka
Website
Annual Reports
Announcements
View AnnouncementsThe total asset value of Shilpa Medicare Ltd stood at ₹ 3,311 Cr as on 31-Mar-25
The share price of Shilpa Medicare Ltd is ₹985.80 (NSE) and ₹986.15 (BSE) as of 13-Jun-2025 IST. Shilpa Medicare Ltd has given a return of 31.52% in the last 3 years.
Shilpa Medicare Ltd has a market capitalisation of ₹ 9,644 Cr as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Shilpa Medicare Ltd is 4.07 times as on 13-Jun-2025, a 27% discount to its peers’ median range of 5.57 times.
The P/E ratio of Shilpa Medicare Ltd is 123.17 times as on 13-Jun-2025, a 219% premium to its peers’ median range of 38.59 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Shilpa Medicare Ltd and enter the required number of quantities and click on buy to purchase the shares of Shilpa Medicare Ltd.
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (APIs), finished dosage formulations, biologicals, and other allopathic pharmaceutical preparations in India, the United States, Europe, and internationally. It's primary oncology APIs include capecitabine, gemcitabine hydrochloride, pemetrexed, axitinib, erlotinib hydrochloride, and irinotecan hydrochloride; and non-oncology APIs, such as ambroxol, tranexmic acid, and ursodeoxycholic acid; as well as novel-drug delivery systems. The company provides contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, and lyophilized injectables. In addition, it is involved in manufacture of specialized oncology formulations; and wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.
The prominent promoters of Shilpa Medicare Ltd. are
Name of promoters | Holding percentage |
---|---|
VISHNUKANT CHATURBHUJ BHUTADA |
6.51%
|
DHARMAVATI BHUTADA |
6.35%
|
RAVI KUMAR INNANI |
4.1%
|
SURAJ KUMAR INANI |
4.01%
|
OM PRAKASH INANI |
2.93%
|
The chairman of the company is Omprakash Inani, and the managing director is Vishnukant Bhutada.
The promoters of Shilpa Medicare Ltd have pledged 3.5% of the total equity as on Mar-25.
Some of the close peers are:
Company | Market Cap(₹ Cr) |
---|---|
9,692
|
|
8,142
|
|
7,752
|
|
5,552
|
|
3,729
|
|
2,767
|
|
2,021
|
|
2,017
|
|
1,950
|
Shilpa Medicare Ltd. | Ratios |
---|---|
Return on equity(%)
|
4.67
|
Operating margin(%)
|
15.86
|
Net Margin(%)
|
6.08
|
Dividend yield(%)
|
0.1
|
Yes, TTM profit after tax of Shilpa Medicare Ltd was ₹78 Cr.